Skip to main content
Signal8

Santhera Pharmaceuticals Holding AG (SPHDF)

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Sector: Biotechnology

Industry: Biotechnology

Santhera Pharmaceuticals Holding AG logo

Santhera Pharmaceuticals Holding AG

OTC:SPHDFHealthcare
CLOSED
Mkt Cap-
EV-
Float10.98M
O/S15.31M
VOL110 sh
$ Vol$2K
Inst Own-
SI1.5%
Net Cash/Sh-
EarningsApr 29 · in 5mo
Dilution